No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
XBI240524P91000
- 2.17
- 0.000.00%
15min DelayTrading May 24 15:51 ET
0.00High0.00Low
0.00Open2.17Pre Close0 Volume0 Open Interest91.00Strike Price0.00Turnover854.20%IV-3.94%PremiumMay 24, 2024Expiry Date0.00Intrinsic Value100Multiplier-9DDays to Expiry2.17Extrinsic Value100Contract SizeAmericanOptions Type-0.6762Delta0.0808Gamma42.61Leverage Ratio-65.0037Theta0.0000Rho-28.81Eff Leverage0.0019Vega
Intraday
- 5D
- 1D
News
Health Care Is Still Very Crowded but Trades at a Discount Vs. History - BofA
The health care sector (NYSEARCA:XLV) is crowded despite a reversal on the recession outlook, according to BofA Securities’ Sector Focus Point report.
Top ETFs With the Most and Least Options Activity - Barclays
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
'This Will Be a Little Bit Worse Than a Normal Correction': April's Stock-market Selloff Isn't Over yet
Technical analysts Ralph Acampora, Larry Williams and Vance Howard see market weakness ahead.
Comments
Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
3
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Pfizer(PFE.US$ $Dynavax Technologies(DVAX.US$ $Sandstorm Gold(SAND.US$ $Bristol-Myers Squibb(BMY.US$ $SPDR S&P Biotech ETF(XBI.US$
$Pfizer(PFE.US$ $Dynavax Technologies(DVAX.US$ $Sandstorm Gold(SAND.US$ $Bristol-Myers Squibb(BMY.US$ $SPDR S&P Biotech ETF(XBI.US$
10
1
$SPDR S&P Biotech ETF(XBI.US$
Assumptions: Overall market is stable and not turning into bear market; US economy no recession; Better to start rate cut in 2024.
$Nasdaq Composite Index(.IXIC.US$ $S&P 500 Index(.SPX.US$
Assumptions: Overall market is stable and not turning into bear market; US economy no recession; Better to start rate cut in 2024.
$Nasdaq Composite Index(.IXIC.US$ $S&P 500 Index(.SPX.US$
1
1
$SPDR S&P Biotech ETF(XBI.US$ $iShares Biotechnology ETF(IBB.US$
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US$ 's $4.3 b...
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US$ 's $4.3 b...
6
Read more